LAS VEGAS — In this video from the American Academy of Orthopaedic Surgeons Annual Meeting, Nicola Fabbri, MD, discussed the use of tranexamic acid for patients with metastatic cancer who undergo total hip arthroplasty or hemiarthroplasty.
“Historically, the use of tranexamic acid has been seen as potentially not safe in the cancer population because of the increased risk for thromboembolic disease,” Fabbri said. “[Tranexamic acid] This study demonstrated that transfusions and perioperative bleeding can be reduced safely and effectively without increasing the risk.
